Stopping Ozempic, Wegovy or Mounjaro does not have to reset the clock to zero. Stopping without preparation does. Clinical trials show this with rare clarity: when the medication stops and nothing takes its place, appetite returns, weight climbs back and most of the benefits on blood pressure, blood sugar and lipids fade. When you prepare the maintenance phase, the picture changes.
In 2022, the extension of the STEP 1 trial followed adults for one year after they stopped semaglutide: they had regained about two thirds of the weight they had lost. In January 2026, a meta-analysis published in the BMJ pooled 37 studies and 9,341 participants: after stopping semaglutide or tirzepatide, weight rises by an average of 0.8 kg per month. These figures describe averages, measured mostly after an abrupt stop and without a structured nutrition plan. Above all, they tell you what to prepare.
This guide focuses on a single question: how to get through stopping, dose reduction or the maintenance phase without losing what you have gained. For the basics (mechanisms, effectiveness, side effects, semaglutide versus tirzepatide), see our complete guide to GLP-1 medications.
Our promise at Diaeta: to support you through this transition with personalised nutrition, without hunger and built from foods you find tasty. We always work in coordination with your doctor: the decision to stop, reduce or continue treatment belongs to them, together with you.
Important: do not stop your medication or change its dose without talking to your prescribing doctor. If you have diabetes, stopping can also raise your blood sugar and requires an adjustment to your treatment.
1. The Key Facts in 8 Points
- After stopping semaglutide, STEP 1 participants regained about two thirds of the weight they had lost within one year. On average, they remained 5.6% below their starting weight.
- After stopping tirzepatide (SURMOUNT-4), the placebo group regained 14% of their body weight in one year, while those who continued treatment lost a further 5.5%.
- The BMJ meta-analysis (2026) estimates a return to starting weight about 1.5 years after stopping semaglutide or tirzepatide, and a return of cardiometabolic markers to baseline in under 1.4 years.
- Regaining weight is not a matter of character. Weight loss increases hunger and lowers energy expenditure for months, even years.
- You protect muscle during treatment, not after: enough protein and strength training.
- A lower dose maintains weight better than stopping. In SURMOUNT-MAINTAIN (2026), switching to 5 mg of tirzepatide preserved about 68% of the weight lost, compared with about 43% on placebo.
- Gradual tapering down to zero has little solid evidence to date. Discuss it with your doctor, case by case.
- In Belgium, the Minister of Health refused reimbursement of Wegovy for obesity in June 2026. Cost therefore weighs on the decision to continue or stop, which makes preparing the maintenance phase all the more worthwhile.
2. What Happens After Stopping: The Clinical Trials
Four randomised trials and a recent meta-analysis describe life after treatment. They all ask the same question from different angles: what happens to weight when the medication stops?
2.1 STEP 1 and its extension: one year without semaglutide
In STEP 1, adults living with obesity or overweight received semaglutide 2.4 mg (Wegovy) or placebo for 68 weeks, along with lifestyle support. The semaglutide group lost an average of 17.3% of their body weight. Then both the treatment and the support stopped.
The extension followed 327 participants for one more year. By week 120, the semaglutide group had regained 11.6 percentage points: about two thirds of the loss. The net result remained −5.6% compared with baseline. Blood pressure, HbA1c, CRP and lipids, which had improved during treatment, mostly returned towards their initial values.
One detail matters: regain varied widely from person to person. Some participants kept most of their loss, others regained all of it. The average hides this spread.
2.2 STEP 4: continue or switch to placebo
STEP 4 used a different design. All participants received semaglutide for 20 weeks. Those who had reached the 2.4 mg dose were then randomised to continue semaglutide or switch to placebo for 48 weeks. Between weeks 20 and 68, weight fell by 7.9% on semaglutide and rose by 6.9% on placebo.
2.3 SURMOUNT-4: the same finding with tirzepatide
SURMOUNT-4 repeated this design with tirzepatide (Mounjaro) in adults without diabetes. After 36 weeks of treatment, average weight loss reached 20.9%. Over the following year:
- Tirzepatide continued: a further 5.5% loss.
- Placebo: 14% regain.
- 89.5% of participants on tirzepatide kept at least 80% of their initial loss, compared with 16.6% on placebo.
Even on placebo, weight remained on average 9.9% below baseline after 88 weeks. Regain is substantial, but rarely complete at one year.
2.4 The BMJ meta-analysis (2026): the big picture
An Oxford team pooled 37 studies (9,341 participants) on stopping obesity medications. Average treatment duration: 39 weeks. Average follow-up after stopping: 32 weeks.
| Outcome | All medications | Semaglutide and tirzepatide |
|---|---|---|
| Average monthly regain | 0.4 kg | 0.8 kg |
| Estimated return to starting weight | About 1.7 years | About 1.5 years |
| Cardiometabolic markers | Estimated return to baseline values in under 1.4 years | |
Two findings deserve your attention. First, weight comes back faster after a medication (0.3 kg more per month) than after a behavioural programme, for the same initial loss. Second, the support programmes offered in these studies did not change the speed of regain. This second point does not mean that food and physical activity are useless: it shows that general advice is not enough against a biology that pushes the other way. The plan has to be more precise, and it has to start before stopping.
Key insight: the trials describe what happens when the medication stops and nothing takes over. Your goal is to build that handover while the treatment still works and hunger stays low.
3. Why the Weight Comes Back: The Biology of Appetite
You will sometimes hear that you "just need to keep good habits". That sentence ignores three well-documented physiological mechanisms.
3.1 The medication clears, hunger returns
Semaglutide and tirzepatide mimic gut hormones (GLP-1, plus GIP for tirzepatide) that slow stomach emptying and calm the appetite centres in the brain. Their half-life is about one week for semaglutide and about five days for tirzepatide, according to their European product information. In practice, the effect on appetite wears off within a few weeks of the last injection.
Many patients then describe the return of "food noise": thinking about the next meal, wanting to snack, finishing the plate without noticing. This is not a personal flaw. It is the baseline state of your regulation system, which the medication had turned down.
3.2 The body defends its former weight
This happens without medication too. In 2011, Sumithran and colleagues followed 50 adults for one year after weight loss. Hormones that stimulate hunger (such as ghrelin) stayed higher, those that curb it (leptin, peptide YY, cholecystokinin) stayed lower, and participants reported more hunger than at the start.
A modelling study published in 2016 put a number on this pull: for each kilo lost, appetite increases by about 100 kcal per day. After a 15 kg loss, the pressure towards regain equals an extra meal every day. The medication neutralised this pressure. Without it, the pressure returns in full.
3.3 Energy expenditure drops more than expected
A lighter body burns less energy, which makes sense. But the drop observed often exceeds what the change in weight and body composition explains: this is adaptive thermogenesis. Rosenbaum and Leibel described it in people maintaining weight loss: more economical muscles, lower thyroid hormones and lower sympathetic nervous activity. We explain these mechanisms in our article on the limits of metabolism calculators.
3.4 Less muscle, less margin
Any large weight loss takes some lean mass with it. Muscle uses energy at rest, serves as a glucose reservoir and determines your everyday strength. Losing a lot of it shrinks your room for manoeuvre afterwards. The next section explains how to limit that loss.
| Mechanism | What changes | Nutrition lever |
|---|---|---|
| End of the medication's effect | Faster stomach emptying, more appetite | Structured meals, rich in protein, fibre and volume |
| Appetite hormones | More ghrelin, less leptin and peptide YY | Foods that stimulate satiety, food order |
| Adaptive thermogenesis | Energy expenditure lower than expected | Daily activity, walking after meals |
| Loss of lean mass | Less muscle, lower resting expenditure | Protein spread across the day, strength training |
For a broader explanation of these mechanisms, read why most weight-loss approaches fail.
4. Protecting Your Muscle During Treatment
The best time to prepare for stopping is during treatment. Your appetite stays low, your meals are smaller, and that is exactly when muscle is most at risk.
4.1 What the trials measure
In a STEP 1 substudy measured by absorptiometry (DXA), lean mass accounted for about 40% of the weight lost on semaglutide. In SURMOUNT-1, on tirzepatide, this share fell to about a quarter. Lean mass is not only muscle (it includes water, organs and bone), but these figures justify close attention.
4.2 Protein: quantity and distribution
In 2025, four American scientific societies (ACLM, ASN, OMA and The Obesity Society) published a joint advisory on nutrition during GLP-1 therapy. It mentions targets of 1.2 to 1.6 g of protein per kilo per day during weight loss or, in the absence of a consensus reference weight, a practical goal of 80 to 120 g per day. Your actual requirement depends on your weight, kidney function, activity and other health conditions: it is calculated individually.
When appetite is low, distribution matters as much as the total:
- Start the meal with the protein portion: you will eat it before you feel full.
- Aim for a protein source at every meal: eggs, skyr or quark, fish, poultry, tofu, tempeh, pulses.
- Choose easy-to-eat formats when nausea dominates: enriched soups, yoghurt smoothies, small pots of quark.
4.3 Strength training: the signal you need
Protein supplies the materials. Strength training gives the order to build. A 2017 review on preserving muscle during weight loss concludes that combining the two limits lean mass loss better than either one alone. The WHO recommends muscle-strengthening activities on at least two days a week for all adults.
A Danish study offers a direct argument for the stopping phase. Adults first lost about 13 kg, then followed a one-year maintenance period with supervised exercise, liraglutide (an older GLP-1), both combined, or placebo. One year after all treatment ended, the liraglutide-only group had regained 6 kg more than the exercise-only group, and 2.5 kg more than the combined group. Exercise done during treatment left a mark that outlasted stopping.
Key insight: during treatment, your priority goes beyond the number on the scale. It covers the quality of the weight you lose. Every week with enough protein and strength training prepares a calmer exit.
5. Reduce the Dose or Stop All at Once?
This is the question our patients ask most often. The honest answer: the evidence is growing but remains limited. And this decision always belongs to your prescribing doctor.
5.1 A lower maintenance dose: SURMOUNT-MAINTAIN
Published in The Lancet in May 2026, the SURMOUNT-MAINTAIN trial treated 441 adults with tirzepatide 10 or 15 mg for 60 weeks. Those who had lost at least 5% of their weight were then assigned to three groups for 52 weeks:
| Maintenance group | Share of weight loss preserved | Total loss from baseline |
|---|---|---|
| Tirzepatide 10 or 15 mg (dose continued) | 96.5% | 21.9% |
| Tirzepatide 5 mg (reduced dose) | 67.9% | 16.6% |
| Placebo (stopped) | 42.8% | 9.9% |
A reduced dose therefore maintains weight far better than stopping, and less well than the full dose. For some people, it can offer a compromise between effectiveness, tolerability and cost. The answer varies from one person to another.
5.2 Gradual tapering to a full stop
Lowering the dose in steps before stopping completely seems intuitive: it gives appetite and habits time to adjust. The data remain thin:
- An observational study presented at the European Congress on Obesity in 2024, run by a Danish digital clinic, followed 54 people who tapered and then stopped semaglutide over about ten weeks. Their weight stayed stable on average after stopping. But the sample is small, the follow-up short, and the study had no control group and was run by the company itself.
- Randomised trials comparing gradual tapering with dose maintenance are under way. Their results have not yet been published.
To date, no tapering schedule has been shown to prevent long-term regain. Be wary of protocols sold as "the method to stop without regaining".
5.3 Questions to prepare with your doctor
- Why are you considering stopping: cost, side effects, goal reached, plans for pregnancy, personal preference?
- Has your weight been stable for several months at your current dose?
- Do you have diabetes, high blood pressure, fatty liver disease or sleep apnoea that could worsen after stopping?
- Could a lower dose be an option?
- What follow-up should you plan: weighing, waist measurement, blood tests, and how often?
- At what amount of weight regain should you reassess the situation together?
Our position: we never change your treatment. We prepare the nutritional ground so that the decision you make with your doctor, whatever it is, goes as smoothly as possible.
6. A Maintenance Plan Built on Satiety and Enjoyment
On a GLP-1, the medication provides an "artificial" satiety. The work of the maintenance phase is to rebuild it on the plate, by choosing foods that fill you up and that you enjoy. A plan that leaves you hungry will not hold up against the biology described above.
6.1 Start before stopping
Ideally, you set up these habits during the last months of treatment, while appetite stays calm. You test meals, you identify the ones that keep you going until the next, and you reach the stopping point with a repertoire you have already tried rather than a list of good intentions.
6.2 Protein, the first pillar of satiety
Of all the macronutrients, protein is the most filling per calorie. A review published in the American Journal of Clinical Nutrition in 2015 links higher protein intakes with better satiety and better preservation of lean mass during weight loss and maintenance. Keep the logic of section 4: a real portion of protein at every meal.
6.3 Fibre and volume
Vegetables, pulses, whole fruit and whole grains add volume for few calories. They fill the stomach, slow digestion and feed the microbiota. A large meta-analysis published in The Lancet in 2019 links an intake of 25 to 29 g of fibre per day with lower body weight and less cardiovascular disease and diabetes.
- A vegetable soup as a starter, hot or cold depending on the season.
- Half a plate of vegetables, roasted, pan-fried or in a salad, seasoned to taste good.
- Pulses (lentils, chickpeas, beans), which combine protein and fibre.
- Whole fruit rather than juice.
Our article on the science of satiety explains these mechanisms in detail.
6.4 Meal structure
During treatment, many patients eat irregularly: appetite is so low that they skip meals. After stopping, this pattern can tip into late-day cravings. Regular meals at fairly stable times help your body anticipate and keep you from arriving at the next meal ravenous. The right number of meals depends on you: three meals, or three meals and a snack, to suit your routine.
6.5 Food order
Eating vegetables and protein first, then starchy foods, reduces the blood sugar spike after the meal. In 2015, Shukla and colleagues measured this in people living with type 2 diabetes: blood sugar rose far less when carbohydrates came at the end of the meal. This strategy removes nothing from the plate, it only changes the order. Find the full protocol in our article on food order and blood sugar.
6.6 Walking after meals
A 10 to 15 minute walk after a meal helps your muscles take up glucose and blunts the blood sugar spike. It also adds daily energy expenditure, a useful lever against adaptive thermogenesis. For the studies in detail, read our article on the post-meal walk.
6.7 Enjoyment, the condition for lasting results
A maintenance plan lasts for years. It must therefore include the dishes you love, family meals, restaurant outings and the Belgian specialities you enjoy. We build these moments into the plan rather than treating them as lapses. Our article Eat what you love shows how.
6.8 Monitoring without worrying
- Regular weighing, for example once a week at the same time, to follow the trend rather than day-to-day fluctuations.
- Waist measurement once a month.
- An alert threshold agreed in advance with your doctor and your dietitian: beyond it, you review the situation together without waiting.
- Blood tests as your doctor advises, especially if you have diabetes or high cholesterol.
| Meal | A filling example | What creates satiety |
|---|---|---|
| Breakfast | Skyr, red berries, nuts and oat flakes | Dairy protein, fibre, quality fats |
| Lunch | Vegetable soup, then a salad of lentils, feta and roasted vegetables | Volume, fibre, plant and animal protein |
| Snack (if needed) | Quark and an apple | Protein and fibre |
| Dinner | Fish fillet, braised chicory, potatoes at the end of the meal | Protein, vegetables first, starchy foods last |
7. Who May Need Long-Term Treatment?
The European Association for the Study of Obesity (EASO) considers obesity a chronic disease. In 2025, it published in Nature Medicine a framework for the pharmacological treatment of obesity and its complications, which places these medications within long-term care.
Nobody is surprised when blood pressure rises again after stopping an antihypertensive. Weight regain after stopping a GLP-1 follows the same logic: the medication treats, it does not cure. This does not mean everyone must continue for life. It means the decision deserves an individual assessment.
Extended treatment, possibly at a reduced dose, may be worth discussing with your doctor, in particular if:
- you live with type 2 diabetes whose control depends on the treatment;
- you have cardiovascular disease, fatty liver disease, sleep apnoea or osteoarthritis that improved with weight loss;
- you have already experienced several large regains after losing weight;
- your weight climbs back quickly despite a well-built maintenance plan.
Other situations point towards stopping: poorly tolerated side effects, plans for pregnancy (these medications are not indicated during pregnancy and stopping them is planned with your doctor), financial constraints. If you have diabetes, our complete guide to type 2 diabetes covers this point further.
8. The Belgian Context: Reimbursement and Cost
8.1 For obesity
On 3 June 2026, the federal Minister of Health, Frank Vandenbroucke, refused reimbursement of Wegovy for the treatment of obesity, following the opinion of the INAMI Drug Reimbursement Committee. He cited the potential cost to health insurance and the fact that the effect disappears after stopping. To our knowledge, no GLP-1 medication is reimbursed in Belgium for obesity alone at the date of publication. You therefore pay for the treatment yourself.
This situation weighs on many decisions to stop. If cost is pushing you to stop, talk to your doctor: a lower dose or a planned stop is better than an abrupt interruption decided alone.
8.2 For type 2 diabetes
Semaglutide (Ozempic) and tirzepatide (Mounjaro) are reimbursed under conditions for type 2 diabetes. A Belgian review published in 2025 describes, for tirzepatide, the same conditions as for other GLP-1s: a BMI of at least 30 kg/m² and an HbA1c above 7.5% despite treatment that includes metformin. These criteria change over time: check your situation with your doctor and your health insurance fund (mutuelle).
8.3 Dietitian consultations
Some Belgian health insurance funds (mutuelles) partly reimburse consultations with a registered dietitian, and INAMI contributes within specific care pathways, for example for type 2 diabetes. Conditions vary by fund and by situation: ask your health insurance fund directly.
9. Frequently Asked Questions
What happens when you stop Ozempic?
The effect on appetite wears off within a few weeks, as the medication is cleared (half-life of about one week). Hunger and food cravings return gradually. Without a maintenance plan, weight rises, and blood pressure, blood sugar and lipids tend to return towards their pre-treatment values. If you have diabetes, your blood sugar may rise: your doctor needs to adjust your treatment.
How much weight do people regain after stopping Wegovy?
In the STEP 1 extension, participants regained about two thirds of the weight they had lost one year after stopping, with large differences between individuals. The 2026 BMJ meta-analysis estimates regain at 0.8 kg per month on average after semaglutide or tirzepatide. These figures mostly concern stops without structured nutrition support.
Is there an Ozempic rebound effect?
On average, the trials do not show regain beyond starting weight in the year after stopping. In both STEP 1 and SURMOUNT-4, participants remained on average below their initial weight one year later. The term "rebound" therefore mostly describes rapid regain, not a systematic overshoot.
Should you taper the dose before stopping?
No solid study to date shows that gradual tapering down to zero prevents regain. SURMOUNT-MAINTAIN does show, however, that a lower maintenance dose of tirzepatide preserves weight better than stopping. The choice between continuing, reducing and stopping is made with your doctor.
Is "withdrawal" the right word?
The word gets used a lot, but it is misleading. What returns after stopping is the physiological appetite that the medication dampened, not a state of craving like a drug withdrawal. Preparation consists of rebuilding satiety with your meals.
Can you stop Mounjaro without regaining weight?
Some people manage it, but SURMOUNT-4 shows that, on average, weight rises markedly after stopping tirzepatide. Your chances improve if you preserved your muscle during treatment, if you reach the stopping point with meals that already fill you up, and if follow-up allows you to react early.
Do you have to take these medications for life?
Not necessarily. EASO considers obesity a chronic disease, and the data show that the effect fades after stopping. Some people benefit from extended treatment, sometimes at a reduced dose. Others stop successfully thanks to a solid maintenance plan. The decision is made with your doctor, based on your health and your priorities.
What should you eat after stopping Ozempic or Wegovy?
Regular meals built around a portion of protein and a generous share of vegetables and fibre, with starchy foods at the end of the meal, and dishes you love. Add a walk after meals and strength training twice a week. A dietitian helps you adapt these principles to your tastes and your health.
Is Wegovy reimbursed in Belgium?
Not for obesity: the Minister of Health refused this reimbursement in June 2026. Ozempic and Mounjaro are reimbursed under conditions for type 2 diabetes. Check your situation with your doctor and your health insurance fund (mutuelle).
10. Our Personalised Approach at Diaeta
In Brussels, we support people at every stage of GLP-1 treatment: at the start, during weight loss, and when the time comes to reduce or stop. The stopping phase is where nutrition support adds the most.
What We Promise You
- Never hungry: we build meals that take over from the medication on satiety, so that stopping does not leave you starving.
- No needless eliminations: your favourite dishes stay on the menu. We adjust portions, order and composition rather than removing foods.
- Evidence-based advice: every recommendation rests on the STEP and SURMOUNT trials and on the guidance of scientific societies.
- Personalised strategies: your protein needs, meal rhythm and activity plan are calculated for you, not for an average.
How We Support You
- Comprehensive assessment: weight history, current treatment, associated conditions, eating habits and food preferences.
- Body composition analysis: we track your lean mass and fat mass, not only your weight, to check that you are preserving your muscle.
- Transition plan: we set up your filling meals during the last months of treatment, before the decision to stop or reduce that you make with your doctor.
- Close follow-up after stopping: more frequent consultations in the months after stopping, with an alert threshold agreed together.
- Coordination with your doctor: we share our observations to help them decide on the next steps of treatment.
Observed Results
With this personalised approach, our patients generally report:
- Better-managed hunger after stopping, thanks to meals built around protein, fibre and volume;
- Better preservation of their muscle mass during treatment;
- More confidence about stopping, because they know what to put on their plate and when to react;
- A calmer relationship with food, with meals they enjoy.
To find out more, see our GLP-1 support and our weight loss support. If you live with diabetes, visit our diabetes page.
Are you thinking about stopping or reducing Ozempic, Wegovy or Mounjaro? Book an appointment for a personalised consultation in Brussels. Together, and in liaison with your doctor, we will prepare a transition without hunger and with meals you love.
Scientific References
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID: 35441470.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. PMID: 38078870.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
- Horn DB, et al. SURMOUNT-MAINTAIN trial (tirzepatide, phase 3b, weight maintenance). Lancet. May 2026.
- West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. PMID: 41500720.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. PMID: 22029981.
- Polidori D, Sanghvi A, Seeley RJ, Hall KD. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity. 2016;24(11):2289-2295. PMID: 27804272.
- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes. 2010;34(Suppl 1):S47-S55. PMID: 20935667.
- Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719-1730. PMID: 33951361.
- Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine. 2024. PMCID: PMC10965408.
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122:344-367.
- Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017;8(3):511-519. PMID: 28507015.
- Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451-1462. PMID: 33239350.
- Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S. PMID: 25926512.
- Reynolds A, Mann J, Cummings J, et al. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434-445. PMID: 30638909.
- Shukla AP, Iliescu RG, Thomas CE, Aronne LJ. Food order has a significant impact on postprandial glucose and insulin levels. Diabetes Care. 2015;38(7):e98-e99. PMID: 26106234.
- McGowan B, et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025;31(10):3229-3232.
- Scheen AJ. Le médicament du mois : le tirzépatide (Mounjaro®). Rev Med Liège. 2025.
- European Medicines Agency (EMA). Summaries of product characteristics: Wegovy (semaglutide) and Mounjaro (tirzepatide).
- Observational study on gradual tapering of semaglutide at a Danish digital clinic (54 participants). Abstract presented at the European Congress on Obesity (ECO), Venice, May 2024.
- Le Spécialiste. Pas de remboursement pour le Wegovy (Vandenbroucke). 3 June 2026.
